Synaptogenix, Inc. (SNPX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol SNPX
- Company Synaptogenix, Inc.
- Price $7.85
- Changes Percentage 29.86
- Change 1.805
- Day Low $5.63
- Day High $7.85
- Year High $8.94
- Year Low $1.84
- Market Cap $10,910,087
- Price Avg 50 EMA (D) $3.64
- Price Avg 200 EMA (D) $3.08
- Exchange NASDAQ
- Volume 980,242
- Average Volume 933,139
- Open $6.26
- Previous Close $6.05
- EPS -10.46
- PE -0.75
- Earnings Announcement 2025-08-08 12:00:00
- Shares Outstanding $1,389,820
Company brief: SYNAPTOGENIX, INC. (SNPX )
- Healthcare
- Biotechnology
- Dr. Alan J. Tuchman M.D., MBA(FAAN)
- https://www.synaptogen.com
- US
- N/A
- 12-08-2020
- US87167T2015
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.